Spruce Biosciences, Inc. Common Stock (SPRB)
PHARMACEUTICAL PREPARATIONS
Spruce Biosciences, Inc. Common Stock (SPRB) is listed on Nasdaq, where it has traded since October 9, 2020.
- Listed On
- Nasdaq
- Listed Since
- October 9, 2020
- Employees
- 8
- Market Cap
- $123M
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 60 institutions reported holding SPRB, with 2.0 million shares worth $108.2 million in aggregate. The largest reported holder was Aigh Capital Management, with 250,000 shares worth $13.5 million. Of the 5 largest holders listed below, 2 opened new positions in SPRB and 3 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Aigh Capital Management | 250,000 | $14M | New position |
| Orbimed Advisors | 200,000 | $11M | New position |
| BlackRock | 187,836 | $10M | Added 1008.96% |
| Millennium Management | 160,981 | $9M | Added 43.88% |
| Vanguard | 156,640 | $8M | Added 544.53% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is SPRB?
Spruce Biosciences, Inc. Common Stock (SPRB) is listed on Nasdaq, where it has traded since October 9, 2020.
Who are the largest institutional holders of SPRB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of SPRB were Aigh Capital Management, Orbimed Advisors and BlackRock.
How many institutions own SPRB?
60 institutions reported a position in SPRB for the quarter ended June 30, 2026, worth $108.2 million in total.
Did institutions buy or sell SPRB last quarter?
Of the 5 largest reported holders, 2 opened new positions in SPRB and 3 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for SPRB.
Every reported institutional holder, plus insider and congressional trades in SPRB, on SentiSense.